You are here: Home: Audio Program Guide: BCU 9 | 2005 Audio: BCU 9 | 2005

  Go to interview with Harold J Burstein, MD, PhD
Go to interview with Charles L Vogel, MD

Go to interview with Eleftherios P Mamounas, MD, MPH

Go to Journal Club's interview

To listen to individual tracks now, click the icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or MP3 for users with other audio players.

Harold J Burstein, MD, PhD
Assistant Professor of Medicine
Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Click here to download the entire interview
Track 1 Introduction by Neil Love, MD
Track 2 Trial E2100: Bevacizumab with paclitaxel as first-line treatment of metastatic disease
Track 3 Progression-free survival as an endpoint in metastatic disease trials
Track 4 Mechanism of action of bevacizumab
Track 5 Integration of bevacizumab into treatment in the metastatic setting
Track 6 Clinical use of nanoparticle albumin-bound (nab) paclitaxel

Track 7 Contraindications for utilization of bevacizumab
Track 8 Future directions in clinical trials of bevacizumab
Track 9 Impact of adjuvant trastuzumab data on future trials of adjuvant chemotherapy
Track 10 Combined analysis of NSABP-B-31/NCCTG-N9831 trials of adjuvant trastuzumab
Track 11 Results of the HERA adjuvant trastuzumab trial
Track 12 Cardiac toxicity data from clinical trials of adjuvant trastuzumab
Track 13 Cardiac safety in BCIRG 006
Track 14 Magnitude of benefit of anthracyclines in patients with HER2-positive disease
Track 15 Impact of adjuvant chemotherapy on patients with ER-positive disease
Track 16 Clinical implications of the adjuvant trastuzumab trial results
Track 17 Clinical use of delayed adjuvant trastuzumab
Track 18 Importance of reliable and accurate HER2 testing for treatment decisions
Track 19 Future adjuvant trials in patients with HER2-positive tumors
Charles L Vogel, MD
Medical Director, Cancer Research Network Inc
Plantation, Florida

Click here to download the entire interview
Track 1 Introduction by Dr Love
Track 2 Integrating aromatase inhibitors into adjuvant therapy of women with ER-positive disease
Track 3 Importance of quality control in hormone receptor testing
Track 4 Approach to adjuvant endocrine therapy in postmenopausal women
Track 5 Management of hormone receptor-positive disease in premenopausal and perimenopausal women
Track 6 Aromatase inhibitors after five years of tamoxifen in postmenopausal women
Track 7 Perspective on emerging data on cardiac events in trials of adjuvant aromatase inhibitors
Track 8 Selection of aromatase inhibitors at different timepoints in the adjuvant setting
Track 9 Approach to and sequencing of therapy of ER-positive metastatic disease
Track 10 Clinical experience with fulvestrant
Track 11 Approach to therapy in patients with HER2-positive metastatic disease
Track 12 Continuation of trastuzumab beyond disease progression
Track 13 Future directions in adjuvant trastuzumab clinical trials
Track 14 Implications of accurate HER2 testing

Eleftherios P Mamounas, MD, MPH
Associate Professor of Surgery
Northeastern Ohio Universities College of Medicine
Medical Director, Aultman Cancer Center
Canton, Ohio

Click here to download the entire interview

Track 1 Introduction by Dr Love
Track 2 Background and rationale for development of the Oncotype DX™ assay
Track 3 Oncotype DX assay to predict prognosis for patients with early breast cancer
Track 4 Utilization of the Oncotype DX assay in clinical practice

Track 5 Perspective on the economics of cancer treatment
Track 6 Recurrence score as a predictor of response to therapy
Track 7 Integration of Oncotype DX assay into clinical practice guidelines
Track 8 Results of NSABP-B-32 sentinel node trial
Track 9 Sentinel lymph node biopsy: Clinical issues in utilization
Track 10 Clinical use of adjuvant aromatase inhibitors in postmenopausal women
Track 11 Planned NSABP trial evaluating optimal duration of aromatase inhibitors
Track 12 Aromatase inhibitors for chemoprevention and treatment of DCIS


Journal Club
Click here to download the entire interview

Track 1 Introduction by Dr Love
Track 2 Dose of capecitabine
Track 3 Integration of bevacizumab into treatment in the metastatic setting
Track 4 Adjuvant endocrine therapy for premenopausal women

Track 5 Switching from tamoxifen to an aromatase inhibitor after chemotherapy-induced menopause
Track 6 Integration of adjuvant trastuzumab into clinical practice
Track 7 Use of fulvestrant in ER-positive metastatic disease